Scripps Translational Science Institute (STSI) announced Friday that it will lead a consortium of four partners to develop a program to improve health outcomes for Ebola patients, increase the safety of health care workers and reduce the risk of spreading the virus to others.
The program, dubbed STAMP2, short for Sensor Technology and Analytics to Monitor, Predict and Protect Ebola Patients, will test a new “precision medicine” approach using wearable, wireless health sensors, a wireless vital signs monitoring platform and advanced analytics technology to monitor and analyze multiple vital signs of patients either suspected or confirmed to be infected with the Ebola virus.
Joining STSI in the new program are San Diego-based wireless vital signs monitor developer Sotera Wireless Inc., San Francisco-based wireless health sensor developer Rhythm Diagnostic Systems, and Illinois-based personalized predictive analytics technology company PhysIQ.
The program was nominated for a grant from the U.S. Agency for International Development (USAID). The grant is part of a new program called Fighting Ebola: A Grand Challenge for Development, led by USAID in collaboration with the White House Office of Science and Technology, the Centers for Disease Control and Prevention, the Department of Defense and field experts to help health care workers provide better care.